Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer On Obamacare Rewind: No Short-Term Impact On Industry

Executive Summary

Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.

You may also be interested in...



Promise Of US Tax Reform Simmers, But On The Backburner

The pharmaceutical industry will have to keep waiting for US tax reform, most likely until at least the end of 2017. President Trump plans to revisit health care reform first to generate the savings needed for "phenomenal" tax reform.

Medicaid Block Grants: Allowing More State Flexibility To Limit Rx Coverage?

Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.

Pharma CEOs Tackle A Tough Question: “Why Don’t People Like You?”

Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC098456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel